Cancer Immunology Immunotherapy

Cancer Immunology, Immunotherapy is a monthly journal from Springer, founded in 1976 and described by its publisher as the oldest specialist title in tumour immunology, publishing basic and translational work on cancer immunology with a 2025 Journal Impact Factor of 5.8.《癌症免疫学与免疫治疗》（Cancer Immunology, Immunotherapy）由（Springer）出版，1976 年创刊，月刊，被出版方称为肿瘤免疫领域历史最久的专业期刊，刊载癌症免疫学的基础与转化研究，2025 年期刊影响因子为 5.8。

Scope

• The journal's stated purpose is to keep readers informed of new results in oncology and immunology, and its remit has widened as the field has grown.期刊的宗旨是让读者了解肿瘤学与免疫学的新成果，其收稿范围随学科发展而不断拓宽。
• Biology concerned with biological response modifiers forms a core strand, covering cytokines, adjuvants and other agents that act on host antitumour immunity.与生物反应调节剂相关的生物学构成核心方向，涵盖细胞因子、佐剂及其他作用于宿主抗肿瘤免疫的制剂。
• Tumour-host interactions are treated as a subject in their own right, from immune escape and tolerance to the composition of the tumour microenvironment.肿瘤与宿主的相互作用被视为独立主题，从免疫逃逸与免疫耐受到肿瘤微环境构成均在其列。
• Clinical immunotherapy is covered, including checkpoint blockade, cellular therapy such as CAR-T cells, vaccines and combination regimens.临床免疫治疗亦在范围内，包括检查点阻断、以（CAR-T）为代表的细胞治疗、疫苗及联合方案。
• Translational work linking laboratory findings to patient selection, biomarkers and response prediction is explicitly encouraged.把实验室发现与患者筛选、生物标志物及疗效预测相衔接的转化研究，受到明确鼓励。
• Formats include short editorials and position papers, general reviews, original articles, brief reports and short communications.稿件类型包括短篇社论与立场文件、一般综述、原创论文、简报与短篇通讯。
• The journal is published in association with the Spanish immunology and immunotherapy group SEI-GEIT, which appears as a society partner on the publisher's site.本刊与西班牙免疫学与免疫治疗学组（SEI-GEIT）合作出版，该学组在出版方网站列为学会合作伙伴。

History

• The first volume appeared in 1976, and Springer's own memorial notice calls it by far the oldest specialist journal in this field.首卷于 1976 年问世，（Springer）的纪念文章称其为该领域历史最久的专业期刊。
• Robert W. Baldwin of Nottingham, who had shown decades earlier that rodent tumours are immunogenic, was editor-in-chief from 1976 until 2003 and stayed on the board afterwards.诺丁汉的 Robert W. Baldwin 自 1976 年至 2003 年任主编，他早年已证明啮齿动物肿瘤具有免疫原性，卸任后仍留在编委会。
• Enrico Mihich and Graham Pawelec followed him as editors-in-chief, and Haidong Dong of the Mayo Clinic took the post on 1 January 2020.其后由 Enrico Mihich 与 Graham Pawelec 继任主编，梅奥诊所的 Haidong Dong 于 2020 年 1 月 1 日接任。
• The title is now online only, and the print ISSN 0340-7004 has been retired in favour of the electronic ISSN 1432-0851.本刊现为纯在线出版，印刷版 ISSN 0340-7004 已停用，仅保留电子 ISSN 1432-0851。
• The 2025 Journal Impact Factor is 5.8, against 5.1 in 2024, 6.63 in 2022 and 6.968 in 2021.2025 年期刊影响因子为 5.8，2024 年为 5.1，2022 年为 6.63，2021 年为 6.968。
• In the 2025 Journal Citation Reports it sits in the first quartile of both oncology, at 67 of 333, and immunology, at 40 of 183, and the median time to first decision is two days.在 2025 年期刊引证报告中，本刊在肿瘤学类 333 种期刊中列第 67 位、免疫学类 183 种中列第 40 位，均属 Q1，投稿至首次决定的中位时间为 2 天。

Editors

• Haidong Dong, professor of immunology and research consultant in urology at the Mayo Clinic, is editor-in-chief and co-discovered B7-H1, now known as PD-L1.主编 Haidong Dong 为梅奥诊所免疫学教授、泌尿科研究顾问，是 B7-H1（即 PD-L1）的共同发现者。
• Five senior associate editors support him, drawn from the Mayo Clinic, Peking Union Medical College, the University of Porto, Nippon Medical School and the University of Hong Kong.五位资深副编辑协助其工作，分别来自梅奥诊所、北京协和医学院、波尔图大学、日本医科大学与香港大学。
• Around fourteen associate editors, based in China, the United States, Germany, Italy and Canada, handle manuscripts across checkpoint biology, cellular therapy and the tumour microenvironment.约十四位副编辑分布在中国、美国、德国、意大利与加拿大，分工覆盖检查点生物学、细胞治疗与肿瘤微环境。
• The editorial board of about eighteen senior investigators spans the United States, Germany, Italy, the United Kingdom, Canada, Japan, Spain, Australia and China.由约十八位资深研究者组成的编委会遍及美国、德国、意大利、英国、加拿大、日本、西班牙、澳大利亚与中国。
• Position papers and short editorials are used to stake out the journal's view on contested clinical questions, alongside conventional research reports.除常规研究报告外，期刊以立场文件与短篇社论就存在争议的临床问题表明立场。
• Authors submit through Springer's online system, and the journal reports 2.3 million downloads in 2025.作者通过（Springer）的在线系统投稿，期刊公布 2025 年下载量为 230 万次。